Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.

The paper describes two people living with HIV whose virus was well controlled and who both had excess visceral abdominal fat, the fat packed around the organs inside the belly. The first patient was not obese, with a BMI of 27 kg/m², and was given tesamorelin, a growth hormone-releasing hormone analog; the authors report that waist circumference fell markedly, lipid levels improved and the patient reported better day-to-day functioning. The second patient was a woman with a higher BMI who was given a GLP-1 receptor agonist, but intermittent access to the drug produced fluctuating weight and persistent abdominal fat; tesamorelin was then added. The paper reports that visceral fat can persist regardless of BMI category and that the two drug classes produced different patterns of response in these two presentations.

Read the paperView on PubMed(opens in a new tab)